Apogee Therapeutics Inc. (APGE)
(Delayed Data from NSDQ)
$45.64 USD
-0.72 (-1.55%)
Updated May 31, 2024 04:00 PM ET
After-Market: $45.72 +0.08 (0.18%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth A Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$45.64 USD
-0.72 (-1.55%)
Updated May 31, 2024 04:00 PM ET
After-Market: $45.72 +0.08 (0.18%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth A Momentum D VGM
Zacks News
Apogee (APGE) Stock Rallies 95.6% in a Month: Here's Why
by Zacks Equity Research
Apogee (APGE) surges 95.6% in a month after reporting positive interim results from its phase I study for APG777 to treat AD. The company plans to initiate a phase II study for the same indication.